GLP-2 Is Not Tirzepatide—and “GLP-3” Is Not Retatrutide

The terms “GLP-2” and “GLP-3” are sometimes used incorrectly as shortcuts for dual- and triple-receptor research compounds. That numbering is scientifically misleading. GLP-2 is a real, distinct proglucagon-derived hormone. “GLP-3” is not the recognized name of a third human glucagon-like peptide, and retatrutide is not GLP-3.

The central distinction

  • Tirzepatide activates the GIP and GLP-1 receptors. It is a dual GIP/GLP-1 receptor agonist—not GLP-2.
  • Retatrutide activates the GIP, GLP-1, and glucagon receptors. It is a triple-receptor agonist—not GLP-3.
  • GLP-2 is its own endogenous peptide hormone with its own receptor, GLP-2R, and is not another name for tirzepatide.

What GLP-1 and GLP-2 actually mean

GLP stands for glucagon-like peptide. Tissue-specific processing of the proglucagon precursor produces recognized peptides that include glucagon, GLP-1, and GLP-2. GLP-1 and GLP-2 are different molecular products with different receptors and biological research contexts. The numbers do not indicate how many receptors a compound activates.

GLP-2 is a 33-amino-acid, intestine-derived peptide studied primarily in intestinal growth, absorption, barrier function, and related physiology. Calling a dual GIP/GLP-1 agonist “GLP-2” erases that established meaning and can create a serious identity error.

Why tirzepatide is not GLP-2

Tirzepatide is an engineered peptide with activity at two receptor systems: the glucose-dependent insulinotropic polypeptide receptor, abbreviated GIPR, and the glucagon-like peptide-1 receptor, abbreviated GLP-1R. FDA prescribing information identifies tirzepatide as a GIP receptor and GLP-1 receptor agonist. Neither “dual agonist” nor “two targets” converts its name into GLP-2.

Why retatrutide is not “GLP-3”

Retatrutide has been studied as one peptide with agonist activity at three receptors: GIPR, GLP-1R, and the glucagon receptor. Researchers may call this a triple-receptor agonist. The “triple” describes the number of receptor targets; it does not create a hormone named GLP-3.

Established human proglucagon nomenclature identifies GLP-1 and GLP-2. “GLP-3” is not the recognized name of a third human glucagon-like peptide in that system. A label or report describing retatrutide only as “GLP-3” therefore fails to state the compound’s accepted identity.

Why this matters on a label or laboratory report

Loose shorthand in conversation is one thing; a mismatch on a bottle, QR destination, specification, or analytical report is a documentation problem. A researcher should not assume that “GLP-2” means tirzepatide or that “GLP-3” means retatrutide.

  • The bottle should identify the specific compound.
  • The analytical report should identify the same compound and chemical form.
  • The lot or sample number should connect the report to the bottle.
  • The expected sequence or molecular mass should correspond to the named material.
  • Receptor-target descriptions should not replace molecular identity.

Example of a broken documentation chain

If a bottle labeled tirzepatide links to a report calling the sample “GLP-2,” the names do not match. If a bottle labeled retatrutide links to a report calling the sample “GLP-3,” the report uses nonstandard shorthand rather than an accepted compound identity. In either situation, the discrepancy should be resolved with the supplier and issuing laboratory before the report is treated as support for that bottle.

Use precise terminology

A clear record would describe tirzepatide as a dual GIP/GLP-1 receptor agonist and retatrutide as a triple GIP/GLP-1/glucagon receptor agonist. It would reserve GLP-2 for the distinct GLP-2 peptide and receptor system.

Primary and official sources

Also read How to Verify a QR-Linked Lab Report, Peptide Sequence, Molecular Mass, and Identity, and the Research Peptide Documentation Checklist.

For laboratory and analytical research education only. This page does not provide medical, dosing, administration, or human-use guidance.

RESEARCH RESOURCE PATHWAY

Continue the documentation review

Use these related public guides to connect terminology, analytical methods, lot records, and report verification.